News
Pro-Palestine Encampment Represents First Major Test for Harvard President Alan Garber
News
Israeli PM Benjamin Netanyahu Condemns Antisemitism at U.S. Colleges Amid Encampment at Harvard
News
‘A Joke’: Nikole Hannah-Jones Says Harvard Should Spend More on Legacy of Slavery Initiative
News
Massachusetts ACLU Demands Harvard Reinstate PSC in Letter
News
LIVE UPDATES: Pro-Palestine Protesters Begin Encampment in Harvard Yard
The dean of the Yale Medical School, whose connections with a major pharmaceutical company were disclosed in recent congressional hearings, will leave Yale to become the president of Memorial-Sloan Kettering Cancer Institute in New York.
Dr. Lewis Thomas, the Yale dean, will resign on July 1, Yale President Kingman Brewster Jr. announced last week.
Thomas was appointed dean last July 1. The briefness of his tenure raised speculation that his resignation was related to the disclosure in congressional hearings last October that Thomas and Robert H. Ebert, dean of the Harvard Medical School, were both paid consultants to the Squibb Corporation, a major pharmaceutical manufacturer.
No Relation
Doubts about a possible conflict of nterest were brought up after the disclosure.
"There is no relation whatsoever between the Squibb thing and my resignation," Thomas, reached at his home in Connecticut, said yesterday.
A spokesman for The Yale Daily News said yesterday that Thomas's new job would be much more prestigious and that his salary would be substantially higher than his present one.
Leading Job
Steve Kezerian, director of Yale's News Bureau, said last week that Thomas' new position will be "one of the leading jobs in the country involving cancer research," the Daily News reported.
President Brewster is naming a special faculty committee to help him in the search for a new dean. However, no obvious candidates have been mentioned for the position.
Thomas came to Yale in 1969 as the chairman of the Department of Pathology.
Want to keep up with breaking news? Subscribe to our email newsletter.